¹⁸F-fluorodeoxyglucose PET/computed tomography for primary brain tumors

Area of Science:

• Neuroimaging
• Oncology
• Nuclear Medicine

Background:

• Computed tomography (CT) and MR imaging are standard for brain tumor diagnosis but rely on morphology and an intact blood-brain barrier.
• These conventional methods do not fully address critical aspects of tumor biology.
• Limitations in differentiating tumor types and assessing tumor behavior exist with current structural imaging.

Purpose of the Study:

• To describe the contemporary applications of 18F-fluorodeoxyglucose (FDG)-PET and FDG-PET/CT in primary brain tumors.
• To highlight how FDG-PET can overcome limitations of conventional imaging modalities.
• To explore the role of FDG-PET in various clinical scenarios of brain tumor management.

Main Methods:

• Utilizing 18F-fluorodeoxyglucose (FDG) as a radiotracer for Positron Emission Tomography (PET).
• Integrating PET with CT (FDG-PET/CT) for combined functional and anatomical information.
• Reviewing current literature and clinical data on FDG-PET applications in primary brain tumors.

Main Results:

• FDG-PET provides crucial information for differentiating primary brain tumor types.
• The modality assists in initial staging and risk stratification of brain tumors.
• FDG-PET is effective for therapy planning, response evaluation, and detecting tumor recurrence.

Conclusions:

• FDG-PET and FDG-PET/CT offer significant advantages over conventional imaging for primary brain tumors.
• These functional imaging techniques provide deeper insights into tumor biology and behavior.
• FDG-PET represents a valuable tool for comprehensive brain tumor management, from diagnosis to follow-up.